Current and emerging trends in prostate cancer immunotherapy

Area of Science:

• Oncology
• Immunology

Background:

• Castration-resistant prostate cancer (CRPC) is a lethal and incurable malignancy, causing significant mortality.
• Despite advances in hormonal therapies, CRPC remains a major clinical challenge.

Purpose of the Study:

• To review emerging developments in immunotherapy for prostate cancer.
• To explore the potential of therapeutic vaccines and checkpoint inhibitors in advanced prostate cancer.

Main Methods:

• Review of recent studies on prostate cancer immunotherapy, including therapeutic vaccines (sipuleucel-T, autologous, allogeneic, viral vector-based) and checkpoint inhibitors (CTLA-4, PD-1/PD-L1).
• Examination of the applicability of current response assessment metrics to immunotherapies.

Main Results:

• Therapeutic vaccines and checkpoint inhibitors are under investigation for advanced prostate cancer.
• Existing response evaluation criteria for cytotoxic therapies may not be suitable for immunotherapies.
• Early findings suggest combination therapies might be necessary for optimal outcomes.

Conclusions:

• Immunotherapy represents a promising frontier in advanced prostate cancer treatment.
• Further research is needed to establish optimal immunotherapy strategies, including combination approaches and novel response assessment methods.